nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—TYMS—pancreatic cancer	0.153	1	CbGaD
Methotrexate—esophageal cancer—pancreatic cancer	0.131	0.324	CtDrD
Methotrexate—colon cancer—pancreatic cancer	0.109	0.271	CtDrD
Methotrexate—stomach cancer—pancreatic cancer	0.0888	0.22	CtDrD
Methotrexate—germ cell cancer—pancreatic cancer	0.0744	0.185	CtDrD
Methotrexate—PGD—Dacarbazine—pancreatic cancer	0.0481	0.16	CbGbCtD
Methotrexate—MTHFR—Fluorouracil—pancreatic cancer	0.0231	0.0768	CbGbCtD
Methotrexate—TYMS—Gemcitabine—pancreatic cancer	0.023	0.0765	CbGbCtD
Methotrexate—TYMS—Fluorouracil—pancreatic cancer	0.0196	0.0655	CbGbCtD
Methotrexate—ABCC10—Gemcitabine—pancreatic cancer	0.0189	0.0631	CbGbCtD
Methotrexate—ABCC10—Docetaxel—pancreatic cancer	0.0124	0.0412	CbGbCtD
Methotrexate—ABCC3—Fluorouracil—pancreatic cancer	0.0102	0.0339	CbGbCtD
Methotrexate—ABCC10—Doxorubicin—pancreatic cancer	0.00922	0.0307	CbGbCtD
Methotrexate—SLC22A7—Fluorouracil—pancreatic cancer	0.00797	0.0265	CbGbCtD
Methotrexate—ABCC4—Fluorouracil—pancreatic cancer	0.00778	0.0259	CbGbCtD
Methotrexate—SLCO1B3—Docetaxel—pancreatic cancer	0.00691	0.023	CbGbCtD
Methotrexate—ABCC1—Epirubicin—pancreatic cancer	0.0067	0.0223	CbGbCtD
Methotrexate—ABCC1—Irinotecan—pancreatic cancer	0.00652	0.0217	CbGbCtD
Methotrexate—ABCC2—Tamoxifen—pancreatic cancer	0.00628	0.0209	CbGbCtD
Methotrexate—SLC22A7—Docetaxel—pancreatic cancer	0.00608	0.0203	CbGbCtD
Methotrexate—ABCC4—Sunitinib—pancreatic cancer	0.00592	0.0197	CbGbCtD
Methotrexate—ABCC3—Doxorubicin—pancreatic cancer	0.0058	0.0193	CbGbCtD
Methotrexate—ABCG2—Tamoxifen—pancreatic cancer	0.00568	0.0189	CbGbCtD
Methotrexate—SLCO1B1—Irinotecan—pancreatic cancer	0.00549	0.0183	CbGbCtD
Methotrexate—ABCG2—Erlotinib—pancreatic cancer	0.00483	0.0161	CbGbCtD
Methotrexate—ABCC2—Irinotecan—pancreatic cancer	0.00482	0.0161	CbGbCtD
Methotrexate—ABCC1—Docetaxel—pancreatic cancer	0.00478	0.0159	CbGbCtD
Methotrexate—ABCG2—Irinotecan—pancreatic cancer	0.00436	0.0145	CbGbCtD
Methotrexate—ABCG2—Fluorouracil—pancreatic cancer	0.00419	0.0139	CbGbCtD
Methotrexate—ABCC1—Doxorubicin—pancreatic cancer	0.00356	0.0119	CbGbCtD
Methotrexate—ABCC2—Docetaxel—pancreatic cancer	0.00354	0.0118	CbGbCtD
Methotrexate—ABCC2—Sunitinib—pancreatic cancer	0.00352	0.0117	CbGbCtD
Methotrexate—ALB—Erlotinib—pancreatic cancer	0.00333	0.0111	CbGbCtD
Methotrexate—ABCG2—Docetaxel—pancreatic cancer	0.0032	0.0106	CbGbCtD
Methotrexate—ABCG2—Sunitinib—pancreatic cancer	0.00318	0.0106	CbGbCtD
Methotrexate—ALB—Irinotecan—pancreatic cancer	0.00301	0.01	CbGbCtD
Methotrexate—ALB—Fluorouracil—pancreatic cancer	0.00289	0.00961	CbGbCtD
Methotrexate—ABCC2—Doxorubicin—pancreatic cancer	0.00264	0.00878	CbGbCtD
Methotrexate—ABCC3—bile duct—pancreatic cancer	0.0026	0.155	CbGeAlD
Methotrexate—ABCG2—Doxorubicin—pancreatic cancer	0.00238	0.00794	CbGbCtD
Methotrexate—ABCC2—bile duct—pancreatic cancer	0.00207	0.124	CbGeAlD
Methotrexate—ABCB1—Tamoxifen—pancreatic cancer	0.00205	0.00682	CbGbCtD
Methotrexate—ABCB1—Gemcitabine—pancreatic cancer	0.00176	0.00588	CbGbCtD
Methotrexate—ABCB1—Erlotinib—pancreatic cancer	0.00174	0.0058	CbGbCtD
Methotrexate—ABCC2—bile—pancreatic cancer	0.00159	0.0953	CbGeAlD
Methotrexate—ABCB1—Irinotecan—pancreatic cancer	0.00157	0.00524	CbGbCtD
Methotrexate—ABCB1—Docetaxel—pancreatic cancer	0.00115	0.00384	CbGbCtD
Methotrexate—ABCB1—Sunitinib—pancreatic cancer	0.00115	0.00382	CbGbCtD
Methotrexate—Pemetrexed—SLC29A1—pancreatic cancer	0.000868	0.353	CrCbGaD
Methotrexate—ABCB1—Doxorubicin—pancreatic cancer	0.000859	0.00286	CbGbCtD
Methotrexate—FPGS—islet of Langerhans—pancreatic cancer	0.000675	0.0403	CbGeAlD
Methotrexate—SLC19A1—digestive system—pancreatic cancer	0.000608	0.0363	CbGeAlD
Methotrexate—AOX1—gall bladder—pancreatic cancer	0.000566	0.0338	CbGeAlD
Methotrexate—ABCC3—gall bladder—pancreatic cancer	0.000554	0.0331	CbGeAlD
Methotrexate—GGH—pancreas—pancreatic cancer	0.000539	0.0322	CbGeAlD
Methotrexate—Raltitrexed—TYMS—pancreatic cancer	0.00051	0.207	CrCbGaD
Methotrexate—ALB—gall bladder—pancreatic cancer	0.000472	0.0282	CbGeAlD
Methotrexate—SLC46A1—digestive system—pancreatic cancer	0.000468	0.028	CbGeAlD
Methotrexate—GGH—digestive system—pancreatic cancer	0.000461	0.0275	CbGeAlD
Methotrexate—ATIC—pancreas—pancreatic cancer	0.000459	0.0274	CbGeAlD
Methotrexate—PGD—islet of Langerhans—pancreatic cancer	0.000421	0.0252	CbGeAlD
Methotrexate—FPGS—digestive system—pancreatic cancer	0.000405	0.0242	CbGeAlD
Methotrexate—TYMS—Paclitaxel—Docetaxel—pancreatic cancer	0.000393	0.451	CbGdCrCtD
Methotrexate—ATIC—digestive system—pancreatic cancer	0.000392	0.0234	CbGeAlD
Methotrexate—Pralatrexate—TYMS—pancreatic cancer	0.000387	0.157	CrCbGaD
Methotrexate—Leucovorin—TYMS—pancreatic cancer	0.000387	0.157	CrCbGaD
Methotrexate—TYMS—Gefitinib—Erlotinib—pancreatic cancer	0.000377	0.433	CbGdCrCtD
Methotrexate—AOX1—islet of Langerhans—pancreatic cancer	0.000371	0.0222	CbGeAlD
Methotrexate—SLC22A11—digestive system—pancreatic cancer	0.000316	0.0189	CbGeAlD
Methotrexate—Pemetrexed—TYMS—pancreatic cancer	0.000309	0.126	CrCbGaD
Methotrexate—SLC22A7—digestive system—pancreatic cancer	0.000309	0.0185	CbGeAlD
Methotrexate—MTHFR—digestive system—pancreatic cancer	0.000291	0.0174	CbGeAlD
Methotrexate—TYMS—digestive system—pancreatic cancer	0.000266	0.0159	CbGeAlD
Methotrexate—DHFR—digestive system—pancreatic cancer	0.000263	0.0157	CbGeAlD
Methotrexate—AOX1—pancreas—pancreatic cancer	0.000261	0.0156	CbGeAlD
Methotrexate—PGD—digestive system—pancreatic cancer	0.000253	0.0151	CbGeAlD
Methotrexate—SLC16A1—digestive system—pancreatic cancer	0.000236	0.0141	CbGeAlD
Methotrexate—SLCO1B1—digestive system—pancreatic cancer	0.00023	0.0137	CbGeAlD
Methotrexate—AOX1—digestive system—pancreatic cancer	0.000223	0.0133	CbGeAlD
Methotrexate—ABCC3—digestive system—pancreatic cancer	0.000218	0.013	CbGeAlD
Methotrexate—ABCC10—digestive system—pancreatic cancer	0.000217	0.013	CbGeAlD
Methotrexate—ABCC4—pancreas—pancreatic cancer	0.000211	0.0126	CbGeAlD
Methotrexate—SLCO1A2—digestive system—pancreatic cancer	0.000187	0.0112	CbGeAlD
Methotrexate—ABCC4—digestive system—pancreatic cancer	0.00018	0.0108	CbGeAlD
Methotrexate—ABCC2—digestive system—pancreatic cancer	0.000174	0.0104	CbGeAlD
Methotrexate—ABCB1—islet of Langerhans—pancreatic cancer	0.000104	0.00623	CbGeAlD
Methotrexate—TYMS—Azacitidine—Gemcitabine—pancreatic cancer	0.000102	0.117	CbGdCrCtD
Methotrexate—ABCB1—pancreas—pancreatic cancer	7.33e-05	0.00438	CbGeAlD
Methotrexate—ABCB1—digestive system—pancreatic cancer	6.26e-05	0.00374	CbGeAlD
Methotrexate—Feeling abnormal—Fluorouracil—pancreatic cancer	2.77e-05	0.000344	CcSEcCtD
Methotrexate—Anaemia—Docetaxel—pancreatic cancer	2.74e-05	0.000342	CcSEcCtD
Methotrexate—Pancytopenia—Epirubicin—pancreatic cancer	2.73e-05	0.00034	CcSEcCtD
Methotrexate—Vomiting—Sunitinib—pancreatic cancer	2.71e-05	0.000337	CcSEcCtD
Methotrexate—Body temperature increased—Gemcitabine—pancreatic cancer	2.7e-05	0.000336	CcSEcCtD
Methotrexate—Neutropenia—Epirubicin—pancreatic cancer	2.69e-05	0.000335	CcSEcCtD
Methotrexate—Dysuria—Epirubicin—pancreatic cancer	2.69e-05	0.000335	CcSEcCtD
Methotrexate—Rash—Sunitinib—pancreatic cancer	2.68e-05	0.000334	CcSEcCtD
Methotrexate—Dermatitis—Sunitinib—pancreatic cancer	2.68e-05	0.000334	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Epirubicin—pancreatic cancer	2.67e-05	0.000333	CcSEcCtD
Methotrexate—Urticaria—Fluorouracil—pancreatic cancer	2.67e-05	0.000332	CcSEcCtD
Methotrexate—Headache—Sunitinib—pancreatic cancer	2.67e-05	0.000332	CcSEcCtD
Methotrexate—Asthma—Doxorubicin—pancreatic cancer	2.66e-05	0.000331	CcSEcCtD
Methotrexate—Leukopenia—Docetaxel—pancreatic cancer	2.66e-05	0.000331	CcSEcCtD
Methotrexate—Body temperature increased—Fluorouracil—pancreatic cancer	2.65e-05	0.00033	CcSEcCtD
Methotrexate—Eosinophilia—Doxorubicin—pancreatic cancer	2.63e-05	0.000328	CcSEcCtD
Methotrexate—Photosensitivity reaction—Epirubicin—pancreatic cancer	2.62e-05	0.000327	CcSEcCtD
Methotrexate—Pancreatitis—Doxorubicin—pancreatic cancer	2.61e-05	0.000325	CcSEcCtD
Methotrexate—Cough—Docetaxel—pancreatic cancer	2.59e-05	0.000323	CcSEcCtD
Methotrexate—Hypersensitivity—Irinotecan—pancreatic cancer	2.58e-05	0.000321	CcSEcCtD
Methotrexate—Pneumonia—Epirubicin—pancreatic cancer	2.58e-05	0.000321	CcSEcCtD
Methotrexate—Convulsion—Docetaxel—pancreatic cancer	2.57e-05	0.00032	CcSEcCtD
Methotrexate—Drowsiness—Epirubicin—pancreatic cancer	2.56e-05	0.000319	CcSEcCtD
Methotrexate—Infestation—Epirubicin—pancreatic cancer	2.56e-05	0.000319	CcSEcCtD
Methotrexate—Infestation NOS—Epirubicin—pancreatic cancer	2.56e-05	0.000319	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	2.54e-05	0.000316	CcSEcCtD
Methotrexate—Chest pain—Docetaxel—pancreatic cancer	2.53e-05	0.000315	CcSEcCtD
Methotrexate—Myalgia—Docetaxel—pancreatic cancer	2.53e-05	0.000315	CcSEcCtD
Methotrexate—Arthralgia—Docetaxel—pancreatic cancer	2.53e-05	0.000315	CcSEcCtD
Methotrexate—Nausea—Sunitinib—pancreatic cancer	2.53e-05	0.000315	CcSEcCtD
Methotrexate—Pancytopenia—Doxorubicin—pancreatic cancer	2.53e-05	0.000314	CcSEcCtD
Methotrexate—Renal failure—Epirubicin—pancreatic cancer	2.52e-05	0.000314	CcSEcCtD
Methotrexate—Asthenia—Irinotecan—pancreatic cancer	2.52e-05	0.000313	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	2.51e-05	0.000312	CcSEcCtD
Methotrexate—Stomatitis—Epirubicin—pancreatic cancer	2.5e-05	0.000311	CcSEcCtD
Methotrexate—Conjunctivitis—Epirubicin—pancreatic cancer	2.49e-05	0.00031	CcSEcCtD
Methotrexate—Dysuria—Doxorubicin—pancreatic cancer	2.49e-05	0.00031	CcSEcCtD
Methotrexate—Neutropenia—Doxorubicin—pancreatic cancer	2.49e-05	0.00031	CcSEcCtD
Methotrexate—Hypersensitivity—Fluorouracil—pancreatic cancer	2.47e-05	0.000308	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	2.47e-05	0.000308	CcSEcCtD
Methotrexate—Sweating—Epirubicin—pancreatic cancer	2.46e-05	0.000306	CcSEcCtD
Methotrexate—Asthenia—Gemcitabine—pancreatic cancer	2.45e-05	0.000305	CcSEcCtD
Methotrexate—Haematuria—Epirubicin—pancreatic cancer	2.44e-05	0.000304	CcSEcCtD
Methotrexate—Confusional state—Docetaxel—pancreatic cancer	2.44e-05	0.000304	CcSEcCtD
Methotrexate—Photosensitivity reaction—Doxorubicin—pancreatic cancer	2.43e-05	0.000302	CcSEcCtD
Methotrexate—Hepatobiliary disease—Epirubicin—pancreatic cancer	2.42e-05	0.000302	CcSEcCtD
Methotrexate—Anaphylactic shock—Docetaxel—pancreatic cancer	2.42e-05	0.000302	CcSEcCtD
Methotrexate—Epistaxis—Epirubicin—pancreatic cancer	2.42e-05	0.000301	CcSEcCtD
Methotrexate—Pruritus—Gemcitabine—pancreatic cancer	2.42e-05	0.000301	CcSEcCtD
Methotrexate—Infection—Docetaxel—pancreatic cancer	2.41e-05	0.0003	CcSEcCtD
Methotrexate—Diarrhoea—Irinotecan—pancreatic cancer	2.4e-05	0.000299	CcSEcCtD
Methotrexate—Agranulocytosis—Epirubicin—pancreatic cancer	2.39e-05	0.000298	CcSEcCtD
Methotrexate—Pneumonia—Doxorubicin—pancreatic cancer	2.39e-05	0.000297	CcSEcCtD
Methotrexate—Nervous system disorder—Docetaxel—pancreatic cancer	2.38e-05	0.000296	CcSEcCtD
Methotrexate—Pruritus—Fluorouracil—pancreatic cancer	2.38e-05	0.000296	CcSEcCtD
Methotrexate—Thrombocytopenia—Docetaxel—pancreatic cancer	2.37e-05	0.000295	CcSEcCtD
Methotrexate—Infestation—Doxorubicin—pancreatic cancer	2.37e-05	0.000295	CcSEcCtD
Methotrexate—Drowsiness—Doxorubicin—pancreatic cancer	2.37e-05	0.000295	CcSEcCtD
Methotrexate—Infestation NOS—Doxorubicin—pancreatic cancer	2.37e-05	0.000295	CcSEcCtD
Methotrexate—Skin disorder—Docetaxel—pancreatic cancer	2.35e-05	0.000293	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	2.35e-05	0.000293	CcSEcCtD
Methotrexate—Diarrhoea—Gemcitabine—pancreatic cancer	2.34e-05	0.000291	CcSEcCtD
Methotrexate—Renal failure—Doxorubicin—pancreatic cancer	2.33e-05	0.00029	CcSEcCtD
Methotrexate—Dizziness—Irinotecan—pancreatic cancer	2.32e-05	0.000289	CcSEcCtD
Methotrexate—Haemoglobin—Epirubicin—pancreatic cancer	2.31e-05	0.000288	CcSEcCtD
Methotrexate—Stomatitis—Doxorubicin—pancreatic cancer	2.31e-05	0.000288	CcSEcCtD
Methotrexate—Anorexia—Docetaxel—pancreatic cancer	2.31e-05	0.000288	CcSEcCtD
Methotrexate—Conjunctivitis—Doxorubicin—pancreatic cancer	2.31e-05	0.000287	CcSEcCtD
Methotrexate—Haemorrhage—Epirubicin—pancreatic cancer	2.3e-05	0.000286	CcSEcCtD
Methotrexate—Hepatitis—Epirubicin—pancreatic cancer	2.3e-05	0.000286	CcSEcCtD
Methotrexate—Diarrhoea—Fluorouracil—pancreatic cancer	2.3e-05	0.000286	CcSEcCtD
Methotrexate—Pharyngitis—Epirubicin—pancreatic cancer	2.28e-05	0.000284	CcSEcCtD
Methotrexate—Sweating—Doxorubicin—pancreatic cancer	2.27e-05	0.000283	CcSEcCtD
Methotrexate—Urinary tract disorder—Epirubicin—pancreatic cancer	2.27e-05	0.000283	CcSEcCtD
Methotrexate—Hypotension—Docetaxel—pancreatic cancer	2.26e-05	0.000282	CcSEcCtD
Methotrexate—Haematuria—Doxorubicin—pancreatic cancer	2.26e-05	0.000281	CcSEcCtD
Methotrexate—Urethral disorder—Epirubicin—pancreatic cancer	2.26e-05	0.000281	CcSEcCtD
Methotrexate—Hepatobiliary disease—Doxorubicin—pancreatic cancer	2.24e-05	0.000279	CcSEcCtD
Methotrexate—Epistaxis—Doxorubicin—pancreatic cancer	2.24e-05	0.000278	CcSEcCtD
Methotrexate—Vomiting—Irinotecan—pancreatic cancer	2.23e-05	0.000277	CcSEcCtD
Methotrexate—Dizziness—Fluorouracil—pancreatic cancer	2.22e-05	0.000276	CcSEcCtD
Methotrexate—Visual impairment—Epirubicin—pancreatic cancer	2.22e-05	0.000276	CcSEcCtD
Methotrexate—Agranulocytosis—Doxorubicin—pancreatic cancer	2.21e-05	0.000275	CcSEcCtD
Methotrexate—Rash—Irinotecan—pancreatic cancer	2.21e-05	0.000275	CcSEcCtD
Methotrexate—Dermatitis—Irinotecan—pancreatic cancer	2.21e-05	0.000275	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	2.21e-05	0.000275	CcSEcCtD
Methotrexate—Headache—Irinotecan—pancreatic cancer	2.2e-05	0.000273	CcSEcCtD
Methotrexate—Insomnia—Docetaxel—pancreatic cancer	2.19e-05	0.000273	CcSEcCtD
Methotrexate—Paraesthesia—Docetaxel—pancreatic cancer	2.18e-05	0.000271	CcSEcCtD
Methotrexate—Erythema multiforme—Epirubicin—pancreatic cancer	2.18e-05	0.000271	CcSEcCtD
Methotrexate—Vomiting—Gemcitabine—pancreatic cancer	2.17e-05	0.00027	CcSEcCtD
Methotrexate—Dyspnoea—Docetaxel—pancreatic cancer	2.16e-05	0.000269	CcSEcCtD
Methotrexate—Somnolence—Docetaxel—pancreatic cancer	2.15e-05	0.000268	CcSEcCtD
Methotrexate—Rash—Gemcitabine—pancreatic cancer	2.15e-05	0.000268	CcSEcCtD
Methotrexate—Dermatitis—Gemcitabine—pancreatic cancer	2.15e-05	0.000268	CcSEcCtD
Methotrexate—Eye disorder—Epirubicin—pancreatic cancer	2.15e-05	0.000268	CcSEcCtD
Methotrexate—Tinnitus—Epirubicin—pancreatic cancer	2.15e-05	0.000267	CcSEcCtD
Methotrexate—Haemoglobin—Doxorubicin—pancreatic cancer	2.14e-05	0.000266	CcSEcCtD
Methotrexate—Headache—Gemcitabine—pancreatic cancer	2.14e-05	0.000266	CcSEcCtD
Methotrexate—Cardiac disorder—Epirubicin—pancreatic cancer	2.14e-05	0.000266	CcSEcCtD
Methotrexate—Vomiting—Fluorouracil—pancreatic cancer	2.14e-05	0.000266	CcSEcCtD
Methotrexate—Dyspepsia—Docetaxel—pancreatic cancer	2.13e-05	0.000266	CcSEcCtD
Methotrexate—Haemorrhage—Doxorubicin—pancreatic cancer	2.13e-05	0.000265	CcSEcCtD
Methotrexate—Hepatitis—Doxorubicin—pancreatic cancer	2.13e-05	0.000265	CcSEcCtD
Methotrexate—Rash—Fluorouracil—pancreatic cancer	2.12e-05	0.000263	CcSEcCtD
Methotrexate—Dermatitis—Fluorouracil—pancreatic cancer	2.12e-05	0.000263	CcSEcCtD
Methotrexate—Pharyngitis—Doxorubicin—pancreatic cancer	2.11e-05	0.000263	CcSEcCtD
Methotrexate—Decreased appetite—Docetaxel—pancreatic cancer	2.11e-05	0.000262	CcSEcCtD
Methotrexate—Headache—Fluorouracil—pancreatic cancer	2.1e-05	0.000262	CcSEcCtD
Methotrexate—Urinary tract disorder—Doxorubicin—pancreatic cancer	2.1e-05	0.000262	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Docetaxel—pancreatic cancer	2.09e-05	0.00026	CcSEcCtD
Methotrexate—Fatigue—Docetaxel—pancreatic cancer	2.09e-05	0.00026	CcSEcCtD
Methotrexate—Angiopathy—Epirubicin—pancreatic cancer	2.09e-05	0.00026	CcSEcCtD
Methotrexate—Urethral disorder—Doxorubicin—pancreatic cancer	2.09e-05	0.00026	CcSEcCtD
Methotrexate—Nausea—Irinotecan—pancreatic cancer	2.08e-05	0.000259	CcSEcCtD
Methotrexate—Immune system disorder—Epirubicin—pancreatic cancer	2.08e-05	0.000259	CcSEcCtD
Methotrexate—Mediastinal disorder—Epirubicin—pancreatic cancer	2.07e-05	0.000258	CcSEcCtD
Methotrexate—Pain—Docetaxel—pancreatic cancer	2.07e-05	0.000258	CcSEcCtD
Methotrexate—Chills—Epirubicin—pancreatic cancer	2.06e-05	0.000257	CcSEcCtD
Methotrexate—Visual impairment—Doxorubicin—pancreatic cancer	2.05e-05	0.000255	CcSEcCtD
Methotrexate—Alopecia—Epirubicin—pancreatic cancer	2.03e-05	0.000253	CcSEcCtD
Methotrexate—Nausea—Gemcitabine—pancreatic cancer	2.03e-05	0.000252	CcSEcCtD
Methotrexate—Mental disorder—Epirubicin—pancreatic cancer	2.02e-05	0.000251	CcSEcCtD
Methotrexate—Erythema multiforme—Doxorubicin—pancreatic cancer	2.01e-05	0.000251	CcSEcCtD
Methotrexate—Malnutrition—Epirubicin—pancreatic cancer	2e-05	0.000249	CcSEcCtD
Methotrexate—Erythema—Epirubicin—pancreatic cancer	2e-05	0.000249	CcSEcCtD
Methotrexate—Feeling abnormal—Docetaxel—pancreatic cancer	2e-05	0.000249	CcSEcCtD
Methotrexate—Nausea—Fluorouracil—pancreatic cancer	1.99e-05	0.000248	CcSEcCtD
Methotrexate—Eye disorder—Doxorubicin—pancreatic cancer	1.99e-05	0.000248	CcSEcCtD
Methotrexate—Tinnitus—Doxorubicin—pancreatic cancer	1.99e-05	0.000247	CcSEcCtD
Methotrexate—Gastrointestinal pain—Docetaxel—pancreatic cancer	1.98e-05	0.000247	CcSEcCtD
Methotrexate—Cardiac disorder—Doxorubicin—pancreatic cancer	1.98e-05	0.000246	CcSEcCtD
Methotrexate—Dysgeusia—Epirubicin—pancreatic cancer	1.96e-05	0.000244	CcSEcCtD
Methotrexate—Back pain—Epirubicin—pancreatic cancer	1.94e-05	0.000241	CcSEcCtD
Methotrexate—Angiopathy—Doxorubicin—pancreatic cancer	1.93e-05	0.00024	CcSEcCtD
Methotrexate—Immune system disorder—Doxorubicin—pancreatic cancer	1.92e-05	0.000239	CcSEcCtD
Methotrexate—Mediastinal disorder—Doxorubicin—pancreatic cancer	1.92e-05	0.000239	CcSEcCtD
Methotrexate—Abdominal pain—Docetaxel—pancreatic cancer	1.92e-05	0.000238	CcSEcCtD
Methotrexate—Body temperature increased—Docetaxel—pancreatic cancer	1.92e-05	0.000238	CcSEcCtD
Methotrexate—Chills—Doxorubicin—pancreatic cancer	1.91e-05	0.000238	CcSEcCtD
Methotrexate—Vision blurred—Epirubicin—pancreatic cancer	1.89e-05	0.000235	CcSEcCtD
Methotrexate—Alopecia—Doxorubicin—pancreatic cancer	1.88e-05	0.000234	CcSEcCtD
Methotrexate—Mental disorder—Doxorubicin—pancreatic cancer	1.87e-05	0.000232	CcSEcCtD
Methotrexate—Ill-defined disorder—Epirubicin—pancreatic cancer	1.86e-05	0.000231	CcSEcCtD
Methotrexate—Malnutrition—Doxorubicin—pancreatic cancer	1.85e-05	0.000231	CcSEcCtD
Methotrexate—Erythema—Doxorubicin—pancreatic cancer	1.85e-05	0.000231	CcSEcCtD
Methotrexate—Anaemia—Epirubicin—pancreatic cancer	1.85e-05	0.00023	CcSEcCtD
Methotrexate—Dysgeusia—Doxorubicin—pancreatic cancer	1.82e-05	0.000226	CcSEcCtD
Methotrexate—Malaise—Epirubicin—pancreatic cancer	1.81e-05	0.000225	CcSEcCtD
Methotrexate—Vertigo—Epirubicin—pancreatic cancer	1.8e-05	0.000224	CcSEcCtD
Methotrexate—Leukopenia—Epirubicin—pancreatic cancer	1.79e-05	0.000223	CcSEcCtD
Methotrexate—Back pain—Doxorubicin—pancreatic cancer	1.79e-05	0.000223	CcSEcCtD
Methotrexate—Hypersensitivity—Docetaxel—pancreatic cancer	1.79e-05	0.000222	CcSEcCtD
Methotrexate—Cough—Epirubicin—pancreatic cancer	1.75e-05	0.000218	CcSEcCtD
Methotrexate—Vision blurred—Doxorubicin—pancreatic cancer	1.75e-05	0.000217	CcSEcCtD
Methotrexate—Asthenia—Docetaxel—pancreatic cancer	1.74e-05	0.000216	CcSEcCtD
Methotrexate—Convulsion—Epirubicin—pancreatic cancer	1.74e-05	0.000216	CcSEcCtD
Methotrexate—Ill-defined disorder—Doxorubicin—pancreatic cancer	1.72e-05	0.000214	CcSEcCtD
Methotrexate—Pruritus—Docetaxel—pancreatic cancer	1.71e-05	0.000213	CcSEcCtD
Methotrexate—Anaemia—Doxorubicin—pancreatic cancer	1.71e-05	0.000213	CcSEcCtD
Methotrexate—Arthralgia—Epirubicin—pancreatic cancer	1.71e-05	0.000212	CcSEcCtD
Methotrexate—Myalgia—Epirubicin—pancreatic cancer	1.71e-05	0.000212	CcSEcCtD
Methotrexate—Chest pain—Epirubicin—pancreatic cancer	1.71e-05	0.000212	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	1.69e-05	0.000211	CcSEcCtD
Methotrexate—Discomfort—Epirubicin—pancreatic cancer	1.68e-05	0.00021	CcSEcCtD
Methotrexate—Malaise—Doxorubicin—pancreatic cancer	1.67e-05	0.000208	CcSEcCtD
Methotrexate—Vertigo—Doxorubicin—pancreatic cancer	1.67e-05	0.000207	CcSEcCtD
Methotrexate—Leukopenia—Doxorubicin—pancreatic cancer	1.66e-05	0.000206	CcSEcCtD
Methotrexate—Diarrhoea—Docetaxel—pancreatic cancer	1.66e-05	0.000206	CcSEcCtD
Methotrexate—Confusional state—Epirubicin—pancreatic cancer	1.65e-05	0.000205	CcSEcCtD
Methotrexate—Anaphylactic shock—Epirubicin—pancreatic cancer	1.63e-05	0.000203	CcSEcCtD
Methotrexate—Infection—Epirubicin—pancreatic cancer	1.62e-05	0.000202	CcSEcCtD
Methotrexate—Cough—Doxorubicin—pancreatic cancer	1.62e-05	0.000201	CcSEcCtD
Methotrexate—Convulsion—Doxorubicin—pancreatic cancer	1.61e-05	0.0002	CcSEcCtD
Methotrexate—Nervous system disorder—Epirubicin—pancreatic cancer	1.6e-05	0.0002	CcSEcCtD
Methotrexate—Dizziness—Docetaxel—pancreatic cancer	1.6e-05	0.000199	CcSEcCtD
Methotrexate—Thrombocytopenia—Epirubicin—pancreatic cancer	1.6e-05	0.000199	CcSEcCtD
Methotrexate—Skin disorder—Epirubicin—pancreatic cancer	1.59e-05	0.000198	CcSEcCtD
Methotrexate—Hyperhidrosis—Epirubicin—pancreatic cancer	1.58e-05	0.000197	CcSEcCtD
Methotrexate—Arthralgia—Doxorubicin—pancreatic cancer	1.58e-05	0.000196	CcSEcCtD
Methotrexate—Myalgia—Doxorubicin—pancreatic cancer	1.58e-05	0.000196	CcSEcCtD
Methotrexate—Chest pain—Doxorubicin—pancreatic cancer	1.58e-05	0.000196	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	1.57e-05	0.000195	CcSEcCtD
Methotrexate—Discomfort—Doxorubicin—pancreatic cancer	1.56e-05	0.000194	CcSEcCtD
Methotrexate—Anorexia—Epirubicin—pancreatic cancer	1.56e-05	0.000194	CcSEcCtD
Methotrexate—Vomiting—Docetaxel—pancreatic cancer	1.54e-05	0.000192	CcSEcCtD
Methotrexate—Rash—Docetaxel—pancreatic cancer	1.53e-05	0.00019	CcSEcCtD
Methotrexate—Hypotension—Epirubicin—pancreatic cancer	1.53e-05	0.00019	CcSEcCtD
Methotrexate—Dermatitis—Docetaxel—pancreatic cancer	1.53e-05	0.00019	CcSEcCtD
Methotrexate—Confusional state—Doxorubicin—pancreatic cancer	1.53e-05	0.00019	CcSEcCtD
Methotrexate—Headache—Docetaxel—pancreatic cancer	1.52e-05	0.000189	CcSEcCtD
Methotrexate—Anaphylactic shock—Doxorubicin—pancreatic cancer	1.51e-05	0.000188	CcSEcCtD
Methotrexate—Infection—Doxorubicin—pancreatic cancer	1.5e-05	0.000187	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	1.49e-05	0.000185	CcSEcCtD
Methotrexate—Nervous system disorder—Doxorubicin—pancreatic cancer	1.48e-05	0.000185	CcSEcCtD
Methotrexate—Thrombocytopenia—Doxorubicin—pancreatic cancer	1.48e-05	0.000184	CcSEcCtD
Methotrexate—Insomnia—Epirubicin—pancreatic cancer	1.48e-05	0.000184	CcSEcCtD
Methotrexate—Skin disorder—Doxorubicin—pancreatic cancer	1.47e-05	0.000183	CcSEcCtD
Methotrexate—Paraesthesia—Epirubicin—pancreatic cancer	1.47e-05	0.000183	CcSEcCtD
Methotrexate—Hyperhidrosis—Doxorubicin—pancreatic cancer	1.46e-05	0.000182	CcSEcCtD
Methotrexate—Dyspnoea—Epirubicin—pancreatic cancer	1.46e-05	0.000181	CcSEcCtD
Methotrexate—Somnolence—Epirubicin—pancreatic cancer	1.45e-05	0.000181	CcSEcCtD
Methotrexate—Anorexia—Doxorubicin—pancreatic cancer	1.44e-05	0.000179	CcSEcCtD
Methotrexate—Nausea—Docetaxel—pancreatic cancer	1.44e-05	0.000179	CcSEcCtD
Methotrexate—Dyspepsia—Epirubicin—pancreatic cancer	1.44e-05	0.000179	CcSEcCtD
Methotrexate—Decreased appetite—Epirubicin—pancreatic cancer	1.42e-05	0.000177	CcSEcCtD
Methotrexate—Hypotension—Doxorubicin—pancreatic cancer	1.41e-05	0.000176	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Epirubicin—pancreatic cancer	1.41e-05	0.000176	CcSEcCtD
Methotrexate—Fatigue—Epirubicin—pancreatic cancer	1.41e-05	0.000175	CcSEcCtD
Methotrexate—Pain—Epirubicin—pancreatic cancer	1.4e-05	0.000174	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	1.38e-05	0.000172	CcSEcCtD
Methotrexate—Insomnia—Doxorubicin—pancreatic cancer	1.37e-05	0.00017	CcSEcCtD
Methotrexate—Paraesthesia—Doxorubicin—pancreatic cancer	1.36e-05	0.000169	CcSEcCtD
Methotrexate—Dyspnoea—Doxorubicin—pancreatic cancer	1.35e-05	0.000168	CcSEcCtD
Methotrexate—Feeling abnormal—Epirubicin—pancreatic cancer	1.35e-05	0.000168	CcSEcCtD
Methotrexate—Somnolence—Doxorubicin—pancreatic cancer	1.34e-05	0.000167	CcSEcCtD
Methotrexate—Gastrointestinal pain—Epirubicin—pancreatic cancer	1.34e-05	0.000166	CcSEcCtD
Methotrexate—Dyspepsia—Doxorubicin—pancreatic cancer	1.33e-05	0.000166	CcSEcCtD
Methotrexate—Decreased appetite—Doxorubicin—pancreatic cancer	1.31e-05	0.000164	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	1.31e-05	0.000163	CcSEcCtD
Methotrexate—Fatigue—Doxorubicin—pancreatic cancer	1.3e-05	0.000162	CcSEcCtD
Methotrexate—Urticaria—Epirubicin—pancreatic cancer	1.3e-05	0.000162	CcSEcCtD
Methotrexate—Pain—Doxorubicin—pancreatic cancer	1.29e-05	0.000161	CcSEcCtD
Methotrexate—Abdominal pain—Epirubicin—pancreatic cancer	1.29e-05	0.000161	CcSEcCtD
Methotrexate—Body temperature increased—Epirubicin—pancreatic cancer	1.29e-05	0.000161	CcSEcCtD
Methotrexate—Feeling abnormal—Doxorubicin—pancreatic cancer	1.25e-05	0.000155	CcSEcCtD
Methotrexate—Gastrointestinal pain—Doxorubicin—pancreatic cancer	1.24e-05	0.000154	CcSEcCtD
Methotrexate—Hypersensitivity—Epirubicin—pancreatic cancer	1.2e-05	0.00015	CcSEcCtD
Methotrexate—Urticaria—Doxorubicin—pancreatic cancer	1.2e-05	0.00015	CcSEcCtD
Methotrexate—Body temperature increased—Doxorubicin—pancreatic cancer	1.2e-05	0.000149	CcSEcCtD
Methotrexate—Abdominal pain—Doxorubicin—pancreatic cancer	1.2e-05	0.000149	CcSEcCtD
Methotrexate—Asthenia—Epirubicin—pancreatic cancer	1.17e-05	0.000146	CcSEcCtD
Methotrexate—Pruritus—Epirubicin—pancreatic cancer	1.16e-05	0.000144	CcSEcCtD
Methotrexate—Diarrhoea—Epirubicin—pancreatic cancer	1.12e-05	0.000139	CcSEcCtD
Methotrexate—Hypersensitivity—Doxorubicin—pancreatic cancer	1.11e-05	0.000139	CcSEcCtD
Methotrexate—Asthenia—Doxorubicin—pancreatic cancer	1.09e-05	0.000135	CcSEcCtD
Methotrexate—Dizziness—Epirubicin—pancreatic cancer	1.08e-05	0.000135	CcSEcCtD
Methotrexate—Pruritus—Doxorubicin—pancreatic cancer	1.07e-05	0.000133	CcSEcCtD
Methotrexate—Vomiting—Epirubicin—pancreatic cancer	1.04e-05	0.000129	CcSEcCtD
Methotrexate—Diarrhoea—Doxorubicin—pancreatic cancer	1.04e-05	0.000129	CcSEcCtD
Methotrexate—Rash—Epirubicin—pancreatic cancer	1.03e-05	0.000128	CcSEcCtD
Methotrexate—Dermatitis—Epirubicin—pancreatic cancer	1.03e-05	0.000128	CcSEcCtD
Methotrexate—Headache—Epirubicin—pancreatic cancer	1.02e-05	0.000127	CcSEcCtD
Methotrexate—Dizziness—Doxorubicin—pancreatic cancer	1e-05	0.000124	CcSEcCtD
Methotrexate—Nausea—Epirubicin—pancreatic cancer	9.71e-06	0.000121	CcSEcCtD
Methotrexate—Vomiting—Doxorubicin—pancreatic cancer	9.62e-06	0.00012	CcSEcCtD
Methotrexate—Rash—Doxorubicin—pancreatic cancer	9.54e-06	0.000119	CcSEcCtD
Methotrexate—Dermatitis—Doxorubicin—pancreatic cancer	9.53e-06	0.000119	CcSEcCtD
Methotrexate—Headache—Doxorubicin—pancreatic cancer	9.48e-06	0.000118	CcSEcCtD
Methotrexate—Nausea—Doxorubicin—pancreatic cancer	8.99e-06	0.000112	CcSEcCtD
Methotrexate—TYMS—Cell Cycle—TP53—pancreatic cancer	3.61e-06	8.29e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	3.61e-06	8.28e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HES1—pancreatic cancer	3.6e-06	8.26e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—PIK3CB—pancreatic cancer	3.6e-06	8.26e-05	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—AKT1—pancreatic cancer	3.6e-06	8.25e-05	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—AKT1—pancreatic cancer	3.6e-06	8.25e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—CTNNB1—pancreatic cancer	3.59e-06	8.24e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PIK3CG—pancreatic cancer	3.59e-06	8.22e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—PTGS2—pancreatic cancer	3.57e-06	8.18e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—GCG—pancreatic cancer	3.57e-06	8.18e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—SRC—pancreatic cancer	3.55e-06	8.15e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—STK11—pancreatic cancer	3.53e-06	8.09e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—CTNNB1—pancreatic cancer	3.51e-06	8.05e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PTEN—pancreatic cancer	3.5e-06	8.03e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—pancreatic cancer	3.5e-06	8.03e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—APOE—pancreatic cancer	3.49e-06	8.01e-05	CbGpPWpGaD
Methotrexate—PGD—Disease—HRAS—pancreatic cancer	3.47e-06	7.95e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—VEGFA—pancreatic cancer	3.46e-06	7.94e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PIK3CD—pancreatic cancer	3.46e-06	7.94e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PPARG—pancreatic cancer	3.46e-06	7.94e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CD44—pancreatic cancer	3.45e-06	7.9e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CG—pancreatic cancer	3.44e-06	7.88e-05	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—PIK3CA—pancreatic cancer	3.43e-06	7.86e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—PTEN—pancreatic cancer	3.42e-06	7.85e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—pancreatic cancer	3.41e-06	7.82e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PIK3CB—pancreatic cancer	3.4e-06	7.78e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—AKT1—pancreatic cancer	3.38e-06	7.74e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—TYMS—pancreatic cancer	3.37e-06	7.74e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PTGS2—pancreatic cancer	3.36e-06	7.71e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PLAU—pancreatic cancer	3.35e-06	7.69e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—STK11—pancreatic cancer	3.35e-06	7.69e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—KRAS—pancreatic cancer	3.35e-06	7.69e-05	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—AKT1—pancreatic cancer	3.35e-06	7.67e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PIK3CB—pancreatic cancer	3.32e-06	7.6e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PPARG—pancreatic cancer	3.32e-06	7.6e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	3.31e-06	7.6e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	3.31e-06	7.58e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GCG—pancreatic cancer	3.3e-06	7.57e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PTGS2—pancreatic cancer	3.29e-06	7.53e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—SRC—pancreatic cancer	3.25e-06	7.45e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—TYMP—pancreatic cancer	3.2e-06	7.33e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—CTNNB1—pancreatic cancer	3.19e-06	7.32e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—TGFB1—pancreatic cancer	3.18e-06	7.29e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—SRC—pancreatic cancer	3.17e-06	7.28e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TERT—pancreatic cancer	3.16e-06	7.24e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PIK3CD—pancreatic cancer	3.15e-06	7.23e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CG—pancreatic cancer	3.15e-06	7.23e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—APOE—pancreatic cancer	3.15e-06	7.23e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	3.15e-06	7.22e-05	CbGpPWpGaD
Methotrexate—PGD—Metabolism—PIK3CA—pancreatic cancer	3.14e-06	7.19e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—pancreatic cancer	3.14e-06	7.19e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—STAT3—pancreatic cancer	3.13e-06	7.18e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatic cancer	3.13e-06	7.17e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—NRAS—pancreatic cancer	3.13e-06	7.17e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—PTEN—pancreatic cancer	3.11e-06	7.14e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—STK11—pancreatic cancer	3.11e-06	7.12e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—PIK3CA—pancreatic cancer	3.08e-06	7.06e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—pancreatic cancer	3.07e-06	7.03e-05	CbGpPWpGaD
Methotrexate—PGD—Disease—AKT1—pancreatic cancer	3.06e-06	7.02e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—STAT3—pancreatic cancer	3.06e-06	7.02e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—NRAS—pancreatic cancer	3.05e-06	7e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PPARG—pancreatic cancer	3.04e-06	6.97e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—TYMS—pancreatic cancer	3.04e-06	6.96e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CD—pancreatic cancer	3.02e-06	6.93e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HIF1A—pancreatic cancer	3.02e-06	6.92e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PIK3CB—pancreatic cancer	3.02e-06	6.92e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TSC2—pancreatic cancer	3.01e-06	6.91e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	3.01e-06	6.9e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PTGS2—pancreatic cancer	2.99e-06	6.85e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CG—pancreatic cancer	2.98e-06	6.84e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	2.98e-06	6.84e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—TP53—pancreatic cancer	2.98e-06	6.83e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—EGF—pancreatic cancer	2.95e-06	6.76e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—APOE—pancreatic cancer	2.95e-06	6.76e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GLP1R—pancreatic cancer	2.94e-06	6.74e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PTEN—pancreatic cancer	2.93e-06	6.73e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	2.92e-06	6.7e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—MYC—pancreatic cancer	2.91e-06	6.68e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—TGFB1—pancreatic cancer	2.9e-06	6.66e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	2.9e-06	6.65e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—DPYD—pancreatic cancer	2.89e-06	6.63e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—SRC—pancreatic cancer	2.89e-06	6.62e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—TYMS—pancreatic cancer	2.89e-06	6.62e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PTEN—pancreatic cancer	2.87e-06	6.57e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—HRAS—pancreatic cancer	2.85e-06	6.53e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—EGFR—pancreatic cancer	2.85e-06	6.53e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CG—pancreatic cancer	2.84e-06	6.52e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—MYC—pancreatic cancer	2.84e-06	6.52e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—TGFB1—pancreatic cancer	2.84e-06	6.5e-05	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—AKT1—pancreatic cancer	2.8e-06	6.42e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—STAT3—pancreatic cancer	2.78e-06	6.38e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—EGFR—pancreatic cancer	2.78e-06	6.38e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—NRAS—pancreatic cancer	2.78e-06	6.37e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CD—pancreatic cancer	2.77e-06	6.35e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PIK3CB—pancreatic cancer	2.75e-06	6.3e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—SLC2A2—pancreatic cancer	2.75e-06	6.29e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PPARG—pancreatic cancer	2.74e-06	6.29e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—APOE—pancreatic cancer	2.74e-06	6.29e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PTGS2—pancreatic cancer	2.72e-06	6.24e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NOTCH1—pancreatic cancer	2.72e-06	6.24e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	2.72e-06	6.23e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—PIK3CA—pancreatic cancer	2.7e-06	6.2e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—KRAS—pancreatic cancer	2.69e-06	6.17e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—TYMS—pancreatic cancer	2.67e-06	6.13e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	2.66e-06	6.11e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CB—pancreatic cancer	2.63e-06	6.04e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—EGF—pancreatic cancer	2.63e-06	6.03e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—KRAS—pancreatic cancer	2.63e-06	6.02e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CD—pancreatic cancer	2.62e-06	6.01e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	2.62e-06	6.01e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PTGS2—pancreatic cancer	2.61e-06	5.98e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PTEN—pancreatic cancer	2.61e-06	5.98e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	2.6e-06	5.96e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—MYC—pancreatic cancer	2.59e-06	5.93e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—TGFB1—pancreatic cancer	2.58e-06	5.92e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GLP1R—pancreatic cancer	2.58e-06	5.91e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	2.58e-06	5.91e-05	CbGpPWpGaD
Methotrexate—PGD—Metabolism—AKT1—pancreatic cancer	2.56e-06	5.88e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—DPYD—pancreatic cancer	2.53e-06	5.81e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—EGFR—pancreatic cancer	2.53e-06	5.8e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—AKT1—pancreatic cancer	2.52e-06	5.77e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CD—pancreatic cancer	2.5e-06	5.73e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CG—pancreatic cancer	2.48e-06	5.68e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PIK3CA—pancreatic cancer	2.47e-06	5.67e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—APOE—pancreatic cancer	2.47e-06	5.66e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CB—pancreatic cancer	2.42e-06	5.54e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—PIK3CA—pancreatic cancer	2.41e-06	5.53e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SLC2A2—pancreatic cancer	2.41e-06	5.51e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PTGS2—pancreatic cancer	2.39e-06	5.49e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—KRAS—pancreatic cancer	2.39e-06	5.48e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PPARG—pancreatic cancer	2.39e-06	5.48e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	2.39e-06	5.48e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PTEN—pancreatic cancer	2.37e-06	5.44e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—APOE—pancreatic cancer	2.35e-06	5.38e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3CD—pancreatic cancer	2.34e-06	5.36e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	2.34e-06	5.36e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CB—pancreatic cancer	2.29e-06	5.24e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—HRAS—pancreatic cancer	2.29e-06	5.24e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PTEN—pancreatic cancer	2.27e-06	5.22e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—HRAS—pancreatic cancer	2.23e-06	5.12e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CG—pancreatic cancer	2.23e-06	5.11e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	2.22e-06	5.09e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—AKT1—pancreatic cancer	2.21e-06	5.07e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—PIK3CA—pancreatic cancer	2.2e-06	5.04e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CB—pancreatic cancer	2.18e-06	5e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CD—pancreatic cancer	2.18e-06	4.99e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	2.18e-06	4.99e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—APOE—pancreatic cancer	2.17e-06	4.98e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PTGS2—pancreatic cancer	2.16e-06	4.95e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PPARG—pancreatic cancer	2.15e-06	4.93e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CD44—pancreatic cancer	2.13e-06	4.87e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CG—pancreatic cancer	2.12e-06	4.86e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PTEN—pancreatic cancer	2.09e-06	4.78e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	2.08e-06	4.77e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PIK3CA—pancreatic cancer	2.07e-06	4.75e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	2.06e-06	4.73e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PPARG—pancreatic cancer	2.04e-06	4.69e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3CB—pancreatic cancer	2.04e-06	4.67e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GCG—pancreatic cancer	2.04e-06	4.67e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—HRAS—pancreatic cancer	2.03e-06	4.66e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PIK3CA—pancreatic cancer	2.02e-06	4.64e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTGS2—pancreatic cancer	2.02e-06	4.63e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—AKT1—pancreatic cancer	2.02e-06	4.63e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—AKT1—pancreatic cancer	1.97e-06	4.52e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CG—pancreatic cancer	1.96e-06	4.5e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CD—pancreatic cancer	1.96e-06	4.49e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—STK11—pancreatic cancer	1.92e-06	4.39e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CB—pancreatic cancer	1.9e-06	4.35e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PPARG—pancreatic cancer	1.89e-06	4.34e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PTEN—pancreatic cancer	1.88e-06	4.32e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PTGS2—pancreatic cancer	1.88e-06	4.31e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CD44—pancreatic cancer	1.86e-06	4.27e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CD—pancreatic cancer	1.86e-06	4.27e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PIK3CA—pancreatic cancer	1.84e-06	4.22e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—SRC—pancreatic cancer	1.83e-06	4.2e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CTNNB1—pancreatic cancer	1.81e-06	4.14e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.8e-06	4.12e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—AKT1—pancreatic cancer	1.79e-06	4.11e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GCG—pancreatic cancer	1.79e-06	4.09e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—VEGFA—pancreatic cancer	1.78e-06	4.09e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—NRAS—pancreatic cancer	1.76e-06	4.04e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTEN—pancreatic cancer	1.76e-06	4.04e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CD—pancreatic cancer	1.72e-06	3.95e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CB—pancreatic cancer	1.71e-06	3.91e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PTGS2—pancreatic cancer	1.69e-06	3.88e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—AKT1—pancreatic cancer	1.69e-06	3.88e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—STK11—pancreatic cancer	1.68e-06	3.85e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PIK3CA—pancreatic cancer	1.68e-06	3.84e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—AKT1—pancreatic cancer	1.65e-06	3.79e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—TYMS—pancreatic cancer	1.65e-06	3.78e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PTEN—pancreatic cancer	1.64e-06	3.76e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TGFB1—pancreatic cancer	1.64e-06	3.76e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—SRC—pancreatic cancer	1.63e-06	3.75e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CB—pancreatic cancer	1.62e-06	3.72e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PTGS2—pancreatic cancer	1.61e-06	3.69e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CA—pancreatic cancer	1.6e-06	3.68e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—STAT3—pancreatic cancer	1.58e-06	3.61e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NRAS—pancreatic cancer	1.57e-06	3.6e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—KRAS—pancreatic cancer	1.52e-06	3.48e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—AKT1—pancreatic cancer	1.5e-06	3.44e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CB—pancreatic cancer	1.5e-06	3.44e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTGS2—pancreatic cancer	1.49e-06	3.41e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PTEN—pancreatic cancer	1.48e-06	3.38e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CA—pancreatic cancer	1.47e-06	3.38e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MYC—pancreatic cancer	1.46e-06	3.36e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TGFB1—pancreatic cancer	1.46e-06	3.35e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—TYMS—pancreatic cancer	1.44e-06	3.31e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—EGFR—pancreatic cancer	1.43e-06	3.28e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PTEN—pancreatic cancer	1.4e-06	3.21e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CA—pancreatic cancer	1.39e-06	3.2e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—AKT1—pancreatic cancer	1.37e-06	3.14e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—KRAS—pancreatic cancer	1.35e-06	3.1e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TP53—pancreatic cancer	1.35e-06	3.09e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—APOE—pancreatic cancer	1.34e-06	3.07e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CA—pancreatic cancer	1.33e-06	3.05e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—AKT1—pancreatic cancer	1.31e-06	3.01e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTEN—pancreatic cancer	1.3e-06	2.98e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—HRAS—pancreatic cancer	1.29e-06	2.96e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.27e-06	2.91e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3CA—pancreatic cancer	1.24e-06	2.85e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CG—pancreatic cancer	1.21e-06	2.77e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—AKT1—pancreatic cancer	1.2e-06	2.76e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—APOE—pancreatic cancer	1.17e-06	2.69e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PPARG—pancreatic cancer	1.17e-06	2.68e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CA—pancreatic cancer	1.16e-06	2.65e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HRAS—pancreatic cancer	1.15e-06	2.64e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—AKT1—pancreatic cancer	1.14e-06	2.61e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—AKT1—pancreatic cancer	1.09e-06	2.49e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CD—pancreatic cancer	1.06e-06	2.44e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CG—pancreatic cancer	1.06e-06	2.43e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CA—pancreatic cancer	1.04e-06	2.39e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PPARG—pancreatic cancer	1.02e-06	2.35e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—AKT1—pancreatic cancer	1.02e-06	2.33e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CA—pancreatic cancer	9.89e-07	2.27e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—AKT1—pancreatic cancer	9.45e-07	2.17e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CD—pancreatic cancer	9.32e-07	2.14e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CB—pancreatic cancer	9.27e-07	2.13e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTGS2—pancreatic cancer	9.19e-07	2.11e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CA—pancreatic cancer	9.16e-07	2.1e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—AKT1—pancreatic cancer	8.5e-07	1.95e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CB—pancreatic cancer	8.12e-07	1.86e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—AKT1—pancreatic cancer	8.08e-07	1.85e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTGS2—pancreatic cancer	8.05e-07	1.85e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTEN—pancreatic cancer	8.01e-07	1.84e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—AKT1—pancreatic cancer	7.48e-07	1.72e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTEN—pancreatic cancer	7.02e-07	1.61e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CA—pancreatic cancer	5.65e-07	1.3e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CA—pancreatic cancer	4.95e-07	1.14e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—AKT1—pancreatic cancer	4.62e-07	1.06e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—AKT1—pancreatic cancer	4.05e-07	9.28e-06	CbGpPWpGaD
